Evommune Inc. Reports EVO756 Phase 2b AD Trial Failure; Stops AD Development

What Happened

• On Sept. 8, 2026 (8‑K filed Sept. 9, 2026), Evommune, Inc. announced top-line results from its randomized, double‑blind, placebo‑controlled, dose‑ranging Phase 2b trial of EVO756 (an oral MRGPRX2 antagonist) in adults with moderate‑to‑severe atopic dermatitis (AD).
• The trial enrolled 121 adults, included a 12‑week treatment period with follow‑up through Week 14, and did not meet the primary or secondary endpoints at any dose. As a result, Evommune said it will cease development of EVO756 for AD but will continue to evaluate EVO756 for migraine prophylaxis.

Key Details

• Trial size: 121 adults enrolled; 12‑week treatment, follow‑up to Week 14.
• Outcome: Primary and secondary endpoints not met at any dose tested.
• Program decision: Development of EVO756 for atopic dermatitis discontinued; migraine program to continue.
• Cash outlook: Company expects current cash, cash equivalents and investments to fund operations into 2029 based on revised plans.

Why It Matters

• Clinical and valuation impact: A failed Phase 2b in AD is a material clinical setback that removes a near‑term development pathway for EVO756 and removes a potential future revenue driver in dermatology.
• Balance sheet and runway: Management says the company’s cash position is sufficient to fund operations into 2029, which matters for how long Evommune can advance other programs (notably the migraine program) without raising additional capital.
• Next steps for investors: Watch for detailed trial data, updates on the migraine program, and any changes to capital plans or pipeline prioritization in future filings and press releases.